Daniel Sands - True Concepts Medical Technologies, Private Partnering Interview at LSI USA ‘23

Transcription

I am Dan Sands CEO of True Concepts Medical. Our product is a foreign one blood collection device designed to prevent false positives, false negatives and process contamination to prevent to isolate pure uncontaminated blood to accelerate testing and diagnosis of sepsis. Unfortunately, every three seconds somebody dies of sepsis. There are over 40 million patients in the US that present to the IDI with an unknown source of fever, which most physicians will determine and draw blood cultures to see if they're septic. So, the gold standard is to draw blood cultures. So in that process, nearly 72 million people annually present to the DEA and have their blood drawn for cultures. Unfortunately, what happens is during that process, contamination causes high false positive rate so the contamination from the vena puncture, the skin flora, any surface bacteria, it's been proven to cause a high false positive rate. And that problem of if it comes back false positive, patients are admitted to the hospital given unnecessary antibiotics, and which leads to unnecessary costs in our healthcare system to the tune of $8.3 billion annually. So the solution is technologies. It's been proven that if you divert the initial contamination, called the initial diversion technique, has been proven to significantly reduce false positives. And now the CDC is recommending this initial diversion specimen technique as a best practice in a healthcare setting. So this typically is used in the emergency department or ICU. The solution Divya is the first internationally patented foreign one blood collection device and that prevents false positives, false negatives, and also process contamination by isolating isolating pure uncontaminated blood. So that we accelerate that testing and diagnosis of sepsis. So the solution how it works, it was invented by a 27 year veteran nurse, practicing today as an emergency pediatric nurse. So the solution have seen multiple EHRs at the bedside. This solution diverts that initial blood draw through a Vacutainer, which most people are familiar with, it's housed in this device. So the process would go venipuncture This button is pressed it will draw up the first three milliliter of blood which is a contaminated blood. And then we draw up 20 milliliters of clean, uncontaminated blood, this contaminated blood will be sent off for a procalcitonin, which is indicative of sepsis while they're performing the other culture tests. So the sorry, one of the blood culture bottles. So then, the other problem is false negatives. So false negatives are columns by high rate of underfilling of the culture bottles, which can lead to a false negative false negatives are significantly bad, because you're going to be sent home and you actually are septic. And this disease progresses rapidly. And that could cause serious implication. So the this device has graduated. So you can see 10 ML is eight to 10 ML is recommended for each blood culture bottles. So each is dispensed 10 ML, and then 10 ml. So the clinician sees exactly eight to 10 ML is going into that culture bottle to prevent false negatives as well. So our uniqueness in this in this space, there are two companies in the market. And it's early, but this is looks to be a technique that is moving towards a standard of care. And this technology is very innovative, it's streamlined, and can be completed in the current workflow that clinicians and nurses are used to doing. So that are the design of this allows for other biomarkers to be analyzed concurrently, instead of wasting the blood. Other solutions on the market today waste that initial diverted contaminated blood, we repurpose it. So if you think of the 72 million blood draws annually, that's a lot of wasted blood and especially in pediatric situations, you want to draw the minimal amount of blood. So that's again a unique factor of our design. So first time visiting and attending the LSI event after multiple years of seeing the growth of the event. It's great to be here and it's been excellent networking and speaking with multiple investors about our technology.